Capecitabine-Temozolomide in G3 Neuroendocrine Neoplasms

#1405

Introduction: There is no standard second line treatment for G3 neuroendocrine neoplasms (NENs). The sensitivity to platinum combinations of G3 NENs with a Ki67 < 50% remains unclear.

Aim(s): We hypothesize that capecitabine-temozolomide (CAPTEM) could be a valid option in this setting.

Materials and methods: We retrospectively analyzed the outcome of NEN patients treated with CAPTEM in 12 sites in Spain between June/2008 and October/2015.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author:

Authors: Crespo G, Lopez C, Jimenez-Fonseca P, Matos I, Capdevila J,

Keywords: capecitabine, temozolomide, G3 NEN, Ki-67,